Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
about
GPCRs in stem cell functionPI3K/PTEN signaling in angiogenesis and tumorigenesisA comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma modelsTemsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expressionPerifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastomaPhase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.Tissue concentration of systemically administered antineoplastic agents in human brain tumors.Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system.Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study.A pilot microdialysis study in brain tumor patients to assess changes in intracerebral cytokine levels after craniotomy and in response to treatment with a targeted anti-cancer agentmTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignanciesTemozolomide promotes genomic and phenotypic changes in glioblastoma cells.mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02Glioma stem cell signaling: therapeutic opportunities and challenges.Inhibitors of mTOR.Enzyme induction with antiepileptic drugs: cause for concern?Intratumor heterogeneity and its impact on drug distribution and sensitivity.Toward precision medicine in glioblastoma: the promise and the challenges.Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations.Comparative study of rapamycin and temsirolimus demonstrates superimposable anti-tumour potency on prostate cancer cells.Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus.Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiformeBiology of CNS lymphoma and the potential of novel agents.Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data.A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.Issues in developing drugs for primary brain tumors: barriers and toxicities.
P2860
Q27003270-C402D45F-2A20-4742-8C15-B0143450CAE8Q28383083-A8A25E81-AF64-4C40-98DB-DD5947F3F71DQ28485220-C98C3D1C-DB1A-4813-9E28-CAF1A05057D8Q28540142-4A573B3D-EC4E-4061-95C0-A822D3B8F6A1Q28743461-107EF9AD-E3E3-4AD8-B951-768F2D909686Q33747609-992B0B21-5D1F-4298-B4F7-1DE39E399A67Q33755862-B263E17D-BB21-4D24-8248-7D7D86ECC1F7Q33844823-3E97E949-9FB3-44B7-B93D-AE27F89F9222Q34087812-0300A1D0-D512-4B95-B20C-788F801D9B8CQ35091507-18F95099-5A5D-405A-9EE0-12C3C39FF62DQ35827892-B7D7F614-ECE1-4FC5-91DE-5365CAC1C1DEQ36090064-7195E6A3-D7AC-42C6-A51F-B406E5C19B5CQ36156993-35E3948A-1460-4B6C-8D60-E79BEFFA81DBQ36780688-46992C8F-A0AA-47F5-A019-836E23678ABCQ36875981-846394D7-9F76-4FFF-94B0-86D61751F3A2Q36944025-28353FF1-6AE4-4C2F-B657-470AF3F0DB31Q37641248-D8993511-AC73-4C7F-BC81-5BBC57941EB6Q37752381-ECADF3F0-82EA-4668-A069-6FF10922FD51Q37819463-E5A3AEE6-EB2A-46D8-A521-0AE23C2647E9Q38046892-4E3EDDDE-014A-4501-B9C3-871E6C7B6E72Q38211694-0C4B93CB-0C06-4859-8FFD-04C539D8EF6FQ38454659-43088AF2-E84C-463E-ADFE-C5DDBEF4EE6BQ38676891-A2FF47D5-2169-4CE1-9926-D96FF616486AQ39319803-54F5745D-2E7C-4776-82FF-0F037179502BQ39610409-3FF91A52-EC51-4118-ACD4-3B312C1FCDB5Q41677150-CC4EF71F-99BC-4F70-B07C-98FA9417902AQ41962516-43D29C6A-2364-41F2-A2E7-839DB8D988BBQ45985951-40752F18-593F-4426-951F-061F268C950BQ47827207-EBA68EA1-4786-4851-9CAE-7272F6880898Q48786407-68295E16-5869-45DE-9222-EB621CFD2ABFQ48806296-A6A5796C-7F88-41B3-BA06-27705D173251Q50435642-0572D16F-B1FB-4661-8AE8-9AD93BD89E84
P2860
Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Pharmacokinetic and tumor dist ...... th recurrent malignant glioma.
@ast
Pharmacokinetic and tumor dist ...... th recurrent malignant glioma.
@en
type
label
Pharmacokinetic and tumor dist ...... th recurrent malignant glioma.
@ast
Pharmacokinetic and tumor dist ...... th recurrent malignant glioma.
@en
prefLabel
Pharmacokinetic and tumor dist ...... th recurrent malignant glioma.
@ast
Pharmacokinetic and tumor dist ...... th recurrent malignant glioma.
@en
P2093
P2860
P1476
Pharmacokinetic and tumor dist ...... ith recurrent malignant glioma
@en
P2093
Charles Conrad
David Schiff
H Ian Robins
Harry Greenberg
Janet Dancey
Jeffrey Raizer
John G Kuhn
Karen L Fink
Kathleen R Lamborn
Kenneth Hess
P2860
P304
P356
10.1158/1078-0432.CCR-07-0781
P407
P577
2007-12-01T00:00:00Z